+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

D

Actively Recruiting

Researchers are evaluating the effectiveness and safety of plozasiran in adults with severe hypertriglyceridemia who have experienced at least two prior acute pancreatitis episodes, with at least one occurring within the last year before screening. This phase 3, randomized, double-blind study aims to understand how plozasiran impacts the risk of acute pancreatitis in this high-risk population. Participants will be randomly assigned to receive either plozasiran 25 mg or a matching placebo through subcutaneous injections every three months during the double-blind treatment period. They are advised to maintain a low-fat diet and continue their usual lipid-lowering medications. After finishing this period or experiencing an acute pancreatitis event, participants may enter a 12-month open-label extension where all receive plozasiran injections every three months. Throughout the study, participants will undergo regular assessments including measuring the time to the first acute pancreatitis event, changes in fasting triglyceride levels, and patient-reported health and productivity questionnaires. Safety will be monitored by tracking adverse events and cardiovascular outcomes. The study duration spans up to approximately 50 months for the double-blind phase, followed by a 12-month extension, with ongoing evaluations to understand the treatments impact.

Age: 18Years +All GendersPhase 3
140 locations